单核细胞/高密度脂蛋白胆固醇比值与早期糖尿病肾病的相关性研究
Correlation between Monocyte/High-Density Lipoprotein Cholesterol Ratio and Early Diabetic Nephropathy
DOI: 10.12677/ACM.2023.13112496, PDF,   
作者: 王玉金, 侯志梅:新疆医科大学第二附属医院,新疆 乌鲁木齐
关键词: 早期糖尿病肾病炎症MHREDN Inflammation MHR
摘要: 目的探讨新型炎性指标单核细胞/高密度脂蛋白胆固醇比值与EDN的相关性。方法选取2020年12月~2023年7月新疆医科大学第二附属医院收治的62例早期糖尿病肾病患者作为EDN组,另取同期在该院就诊的62例2型糖尿病患者作为对照组。采用全自动血细胞分析仪进行血常规测定,用全自动生化分析仪测定常规生化指标,根据血常规和血脂指标计算出MHR (单核细胞/高密度脂蛋白胆固醇)。采用Spearman法分析MHR与EDN的相关性。结果:EDN组MHR、甘油三酯、血肌酐、尿素氮、单核细胞计数、尿酸、同型半胱氨酸均高于对照组(P < 0.05)。高密度脂蛋白胆固醇低于对照组(P < 0.05)。Spearman相关性分析结果显示,MHR与EDN呈正相关(r = 0.303, P = 0.001)。
Abstract: Objective: To investigate the correlation between the ratio of monocyte/high-density lipoprotein cholesterol and EDN. Methods: A total of 62 patients with early diabetic nephropathy admitted to the Second Affiliated Hospital of Xinjiang Medical University from December 2020 to July 2023 were selected as the EDN group, and 62 patients with type 2 diabetes admitted to the hospital during the same period were selected as the control group. Blood routine was determined by automatic blood cell analyzer, routine biochemical indexes were determined by automatic biochemical analyzer, and MHR was calculated according to blood routine and lipid indexes. The correlation between MHR and EDN was analyzed by Pearson method. Results: The levels of triglyceride, serum creatinine, urea nitrogen, monocyte count, uric acid and homocysteine in EDN group were higher than those in con-trol group (P < 0.05). The levels of MHR, triglycerides, blood creatinine, urea nitrogen, monocyte count, uric acid, and homocysteine in the EDN group were higher than those in the control group (P < 0.05). High density lipoprotein cholesterol is lower than the control group (P < 0.05). Pearson correlation analysis showed that MHR was positively correlated with EDN (r = 0.303, P = 0.001).
文章引用:王玉金, 侯志梅. 单核细胞/高密度脂蛋白胆固醇比值与早期糖尿病肾病的相关性研究[J]. 临床医学进展, 2023, 13(11): 17803-17809. https://doi.org/10.12677/ACM.2023.13112496

参考文献

[1] Sultan, A., Singh, J. and Howarth, F.C. (2020) Mechanisms Underlying Electro-Mechanical Dysfunction in the Zucker Diabetic Fatty Rat Heart: A Model of Obesity and Type 2 Diabetes. Heart Failure Reviews, 25, 873-886. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, Y., Lee, K., Ni, Z. and He, J.C. (2020) Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Disease, 6, 215-25.
[3] Thomas, B. (2019) The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps. Current Diabetes Reports, 19, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, L., Long, J., Jiang, W., et al. (2016) Trends in Chronic Kidney Disease in China. The New England Journal of Medicine, 375, 905-906. [Google Scholar] [CrossRef
[5] Doshi, S.M. and Friedman, A.N. (2017) Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology, 12, 1366-1373. [Google Scholar] [CrossRef
[6] Elsayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., et al. (2023) 17. Diabetes Advocacy: Standards of Care in Diabetes—2023. Diabetes Care, 46, S279-S280.
[7] Fujita, T., Hemmi, S., Kajiwara, M., et al. (2013) Complement-Mediated Chronic Inflammation Is Associated with Diabetic Microvascular Complication. Diabetes/Metabolism Research and Reviews, 29, 220-226. [Google Scholar] [CrossRef] [PubMed]
[8] Landis, R.C., Evans, B.J., Chaturvedi, N. and Haskard, D.O. (2010) Per-sistence of TNFα in Diabetic Wounds. Diabetologia, 53, 1537-1538. [Google Scholar] [CrossRef] [PubMed]
[9] Lontchi-Yimagou, E., Sobngwi, E., Matsha, T.E. and Kengne, A.P. (2013) Diabetes Mellitus and Inflammation. Current Diabetes Reports, 13, 435-444. [Google Scholar] [CrossRef] [PubMed]
[10] Pitocco, D., Tesauro, M., Alessandro, R., Ghirlanda, G. and Car-dillo, C. (2013) Oxidative Stress in Diabetes: Implications for Vascular and Other Complications. International Journal of Molecular Sciences, 14, 21525-21550. [Google Scholar] [CrossRef] [PubMed]
[11] Goldfine, A.B. and Shoelson, S.E. (2017) Therapeutic Approaches Targeting Inflammation for Diabetes and Associated Cardiovascular Risk. Journal of Clinical Investigation, 127, 83-93. [Google Scholar] [CrossRef
[12] Landis, R.C., Quimby, K.R. and Greenidge, A.R. (2018) M1/M2 Macro-phages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets. Current Pharmaceutical Design, 24, 2241-2249. [Google Scholar] [CrossRef] [PubMed]
[13] Franca, C.N., Izar, M.C.O., Hortencio, M.N.S., do Amaral, J.B., Ferreira, C.E.S., Tuleta, I.D., et al. (2017) Monocyte Subtypes and the CCR2 Chemokine Receptor in Car-diovascular Disease. Clinical Science, 131, 1215-1224. [Google Scholar] [CrossRef
[14] Prdali, E. and Waltenberger, J. (2012) Monocyte Function and Traffick-ing in Cardiovascular Disease. Thromb Haemost, 108, 804-811. [Google Scholar] [CrossRef
[15] Groh, L., Keating, S.T., Joosten, L.A.B., Netea, M.G. and Riksen, N.P. (2018) Monocyte and Macrophage Immunometabolism in Atherosclerosis. Seminars in Immunopathology, 40, 203-214. [Google Scholar] [CrossRef] [PubMed]
[16] Choi, S.H., Kim, J.H., Lim, S., Lim, J.Y., Kim, K.W., Park, K.S., et al. (2017) Monocyte Count as a Predictor of Cardiovascular Mortality in Older Korean People. Age Ageing, 46, 433-438. [Google Scholar] [CrossRef] [PubMed]
[17] Soran, H., Hama, S., Yadav, R. and Durrington, P.N. (2012) HDL Functionality. Current Opinion in Lipidology, 23, 353-366. [Google Scholar] [CrossRef
[18] Murphy, A.J., Woollard, K.J., Hoang, A., Mukhamedova, N., Stirzaker, R.A., McCormick, S.P., et al. (2008) High-Density Lipoprotein Reduces the Human Monocyte Inflamma-tory Response. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 2071-2077. [Google Scholar] [CrossRef
[19] Villanueva, D.L.E., Tiongson, M.D., Ramos, J.D. and Llanes, E.J. (2020) Monocyte to Highdensity Lipoprotein Ratio (MHR) as a Predictor of Mortality and Major Adverse Cardiovascular Events (MACE) among ST Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Per-cutaneous Coronary Intervention: A Meta-Analysis. Lipids in Health and Disease, 19, 55.
[20] Kanbay, M., Solak, Y., Unal, H.U., et al. (2014) Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Events in Patients with Chronic Kidney Disease. International Urology and Nephrology, 46, 1619-1625. [Google Scholar] [CrossRef] [PubMed]
[21] Cetin, E.H., Cetin, M.S., Canpolat, U., et al. (2015) Mono-cyte/HDL-Cholesterol Ratio Predicts the Definite Stent Thrombosis after Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Biomarkers in Medicine, 9, 967-977. [Google Scholar] [CrossRef] [PubMed]
[22] Guedes, M. and Pecoits-Filho, R. (2022) Can We Cure Diabetic Kidney Disease? Present and Future Perspectives from a Nephrologist’s Point of View. Journal of Internal Medicine, 291, 165-180. [Google Scholar] [CrossRef] [PubMed]
[23] Guo, J., Gao, Y., Wang, Y., Wang, Z., et al. (2019) Application of Herbal Medicines with Heat-Clearing Property to Anti-Microinflammation in the Treatment of Diabetic Kidney Dis-ease. Evidence-Based Complementary and Alternative Medicine, 2019, Article ID: 6174350. [Google Scholar] [CrossRef] [PubMed]
[24] 朱志伟, 叶玉燕, 陈丽萍, 等. 糖尿病肾病患者自身免疫及微炎症指标间的相关性和肾功能关系的研究[J]. 中国预防医学杂志, 2020, 21(6): 628-631. [Google Scholar] [CrossRef
[25] Johnsen, S.H., Fosse, E., Joakimsen, O., et al. (2005) Monocyte Count Is a Predictor of Novel Plaque Formation: A 7-Year Follow-Up Study of 2610 Persons without Carotid Plaque at Baseline the Tromso Study. Stroke, 36, 715-719. [Google Scholar] [CrossRef
[26] Parthasarathy, S., Barnett, J. and Fong, L.G. (1990) High-Density Lipoprotein Inhibits the Oxidative Modification of Low-Density Lipoprotein. Biochimica et Biophysica Acta, 1044, 275-283. [Google Scholar] [CrossRef
[27] Chen, J.W., Li, C., Liu, Z.H., et al. (2019) The Role of Mon-ocyte to High-Density Lipoprotein Cholesterol Ratio in Prediction of Carotid Intima-Media Thicknessinpatients with Type 2 Diabetes. Frontiers in Endocrinology, 10, Article 191.
[28] Efe, F.K. (2021) The Association between Monocyte HDL Ratio and Albuminuria in Diabetic Nephropathy. Pakistan Journal of Medical Sciences, 37, 1128-1132.